BioSyent to Present at the 2014 Marcum MicroCap Investor Conference
May 23 2014 - 8:00AM
Marketwired
BioSyent to Present at the 2014 Marcum MicroCap Investor Conference
TORONTO, ONTARIO--(Marketwired - May 23, 2014) - BioSyent Inc.
("BioSyent") (TSX-VENTURE:RX) is pleased to announce that CEO René
Goehrum will be making a presentation at the Marcum MicroCap
Conference at 11am (ET), May 29, 2014 at the Grand Hyatt Hotel in
New York City. Mr. Goehrum will provide an overview of the Company
and its corporate activities.
The presentation will be webcast live and may be accessed by
visiting the Investor Center at the www.biosyent.com website or at
the following conference link http://wsw.com/webcast/marcum2/bioyf.
A replay of the webcast will be available for 90 days after the
presentation date. The annual Marcum MicroCap Conference is a
signature showcase for superior quality, under-followed public
companies with less than $500 million in market capitalization.
Mr. Goehrum will be available for 1:1 meetings after his
presentation.These meetings can be arranged via the conference
organizers http://www.marcumllp.com/microcap.
To view and listen to the CEO presentation commenting on First
Quarter 2014 Financial Results released May 16, 2014, please visit
the following link http://www.biosyent.com/q1/.
For a direct market quote (15 minutes delay) for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol
"RX", BioSyent is a profitable growth oriented specialty
pharmaceutical company which searches the globe to in-license or
acquire innovative pharmaceutical products that have been
successfully developed, are safe and effective, and have a proven
track record of improving the lives of patients and supporting the
healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then
acquires the exclusive rights to the product and manages it through
the Canadian governmental regulatory approval process. Once
approved, BioSyent markets the product throughout Canada.
At the date of this press release the Company had 13,776,195
shares issued and outstanding.
BioSyent Inc.Mr. Rene C. GoehrumPresident and CEO(905)
206-0013investors@biosyent.comwww.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024